Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Tempus | 2026 | Post-IPO Debt | Undisclosed | Chicago |
| cAMPfield Therapeutics | 2026 | Series A | Undisclosed | San Diego |
| Mirum Pharmaceuticals | 2026 | Post-IPO Debt | Undisclosed | Foster City |
| Route 92 Medical | 2026 | Private Equity | $50.0M | San Mateo |
| Coultreon Biopharma | 2026 | Series A | Undisclosed | Heverlee |
| Ray Therapeutics | 2026 | Series B | Undisclosed | San Diego |
| Spruce Biosciences | 2026 | Post-IPO Equity | Undisclosed | South San Francisco |
| Terremoto Biosciences | 2026 | Series C | Undisclosed | San Francisco |
| ADCendo | 2026 | Series C | $135.0M | Copenhagen |
| Hemab | 2025 | Series C | $157.0M | Copenhagen |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 1 | Tempus | Post-IPO Debt | Undisclosed | Chicago, United States |
| 2 | cAMPfield Therapeutics | Series A | Undisclosed | San Diego, United States |
| 3 | Mirum Pharmaceuticals | Post-IPO Debt | Undisclosed | Foster City, United States |
| 4 | Route 92 Medical | Private Equity | $50.0M | San Mateo, United States |
| 5 | Coultreon Biopharma | Series A | Undisclosed | Heverlee, Belgium |
| 6 | Ray Therapeutics | Series B | Undisclosed | San Diego, United States |
| 7 | Spruce Biosciences | Post-IPO Equity | Undisclosed | South San Francisco, United States |
| 8 | Terremoto Biosciences | Series C | Undisclosed | San Francisco, United States |
| 9 | ADCendo | Series C | $135.0M | Copenhagen, Denmark |
| 10 | Hemab | Series C | $157.0M | Copenhagen, Denmark |
Tempus develops AI-enabled precision medicine technology that supports clinical decision-making and biomedical research.
cAMPfield Therapeutics is a biotechnology company that specializes on exploration and development activities of therapeutic solutions.
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.
Route 92 Medical is a medical device company developing a catheter to treat stroke.
CoultreonBiopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.
Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.
Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system.
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.
Adcendo is a biotech company that develops antibody-drug conjugates (ADCs) to target cancers with high unmet medical needs.
Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.
Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and respiratory diseases.
The Protein Brewery specializes in developing and making animal-free-based protein in a sustainable way.
Nalu Medical is a medical technology company that offers neurostimulation system designed to treat chronic nerve pain.
Phasecraft develops quantum algorithms and related intellectual property for scientific and industrial applications.
MapLight Therapeutics is a biopharma company that offers a platform designed to discover and develop therapeutics for brain disorders.
Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.
GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases.
Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions.
HepaRegeniX is developing drugs for treating acute and chronic liver diseases.
Sparrow Quantum develope and commercializes photonic quantum chip technology.
Tribune Therapeutics specializes in building promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.
Callio Therapeutics develops next-generation, multi-payload antibody-drug conjugates (ADCs).
Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.
Commit Biologics is a biotechnology research company developing a novel immunotherapy platform for the treatment of cancer.
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Novo Holdings has invested in 154 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Novo Holdings's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Life Science. The firm invests across 24 different industry categories.
Among tracked funding rounds, MapLight Therapeutics received $372.5M in a Series D round. Novo Holdings's total known invested capital is $9.1B.
Novo Holdings's average investment size is $78.5M across its portfolio of 154 companies.
Recent Novo Holdings portfolio additions include Tempus, cAMPfield Therapeutics, Mirum Pharmaceuticals, Route 92 Medical, Coultreon Biopharma. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors